Skip to main content
Journal of Family Medicine and Primary Care logoLink to Journal of Family Medicine and Primary Care
. 2026 Feb 7;15(1):33–38. doi: 10.4103/jfmpc.jfmpc_256_25

Safety and effectiveness of topical dapsone in acne treatment: A review

Sami N Alsuwaidan 1, Tala A Qadoumi 1,✉
PMCID: PMC12975053  PMID: 41816125

ABSTRACT

Oral dapsone is effective in treating several dermatologic conditions, including acne vulgaris. However, the rate of adverse effects of oral dapsone is a concern when prescribing it. Topical dapsone may mitigate these adverse effects and enhance the safety and tolerability of dapsone. Here, we review the published reports and studies to examine the efficacy and safety of topical dapsone in treating acne. A literature review was conducted using the PubMed database. The review considered patient and disease factors, such as the type of acne, acne location, patient gender, age, skin type, and race. Other factors, such as the duration and dosage of treatment, monotherapy versus combination therapy, adverse events, and safety profiles, were also compared. Topical dapsone was well tolerated and effective across a variety of acne presentations and patient subgroups. It showed a favorable safety profile, even in patients with comorbidities, such as G6PD deficiency. We conclude that topical dapsone is safe, effective, and well tolerated in the treatment of acne, contrary to its oral form.

Keywords: Acne, dapsone, efficacy, rosacea, safety, topical

Introduction

Oral dapsone is effective in treating several dermatologic conditions, notably in the treatment of leprosy.[1] It has been used in the management of acne vulgaris since 1961.[2] However, this medication is not devoid of a fair share of side effects. Two to six weeks post-therapy, patients may encounter dapsone hypersensitivity syndrome characterized by a rash, fever, and hepatitis. Patients may also experience anorexia, tachycardia, and pancreatitis. This drug in its oral form has also been implicated in drug-induced lupus erythematosus, exfoliative erythroderma, toxic epidermal necrolysis, and morbilliform eruptions.[3] Oral dapsone has displayed significant side effects even at low dosages, which may result in hesitancy around its use.[1] Luckily, topical formulations of dapsone have been made available. Both 5% and 7.5% dapsone gels are FDA approved for the treatment of acne.[4] Dapsone gel 5% is approved for twice-daily use in the treatment of acne in patients aged 12 years and older.[5] Dapsone gel 7.5% is approved for once-daily use in individuals aged nine years and older.[5]

Acne is a chronic multifactorial inflammatory skin condition that impacts 85% of young adults and adolescents.[6] Acne has a significant negative impact on quality of life.[6] There are several types of acne, with acne vulgaris being the most common. Acne vulgaris is categorized into two subtypes: inflammatory and non-inflammatory.[6] Dapsone, a sulfone antibiotic, possesses anti-inflammatory and antimicrobial properties.[7,8] It was found to have antibacterial activity against Cutibacterium acne, in vitro.[2] Dapsone acts by inhibiting dihydrofolic acid, myeloperoxidase, an enzyme found in neutrophils, and chemoattract signaling that recruits neutrophils.[2] Topical dapsone is available in two concentrations as a gel formulation: 5% gel (applied twice daily) and 7.5% (applied once daily). A pea-sized amount is recommended to be applied to the affected area for 12 weeks to achieve the best results.[9] Response to topical dapsone is influenced by certain factors like the type and severity of acne, as well as patient gender and age. It was more effective in inflammatory acne as compared to non-inflammatory lesions, in females as compared to males with acne and in adults when compared to adolescents.[10] Furthermore, there is some questionability regarding skin permeability of topical dapsone with mixed micelles being used as nanocarriers for dapsone delivery, thereby significantly increasing solubility and permeability.[11] Topical dapsone’s concentration in blood was equivalent to one percent of the 100 mg oral dapsone dose.[12] Systemic levels of topical dapsone were 100–145 times lower than those of oral dapsone.[13,14] Daily systemic levels of 7.5% dapsone gel applied once daily were significantly lower than the 5% gel applied twice daily.[15] Unlike oral dapsone, the safety profile of dapsone gel is well documented, with its safety being advocated even in patients with G6PD deficiency due to minimal hematologic side effects.[16] However, there are reports of rare methemoglobinemia when the prescribed dose was exceeded.[17,18] Care should be taken when combining dapsone gel with trimethoprim–sulfamethoxazole, as this combination may increase the risk of hemolysis in a G6PD-deficient patient.[19]

The antimicrobial and anti-inflammatory properties of dapsone make it most desirable for treating a range of skin disorders.[1] There are many studies that have demonstrated that both dapsone 5% gel and dapsone 7.5% are safe, effective, and well tolerated in patients with acne.[20] This review emphasizes the safety and efficacy profile of topical dapsone, aiming to alleviate some of the hesitancy surrounding its prescription, given the notorious profile of its oral counterpart.

Methods

This study reviewed the available literature on topical dapsone 5% and 7.5% in the treatment of acne. The search strategy was applied to the PubMed medical database. There was no restriction on patients’ ethnic group, age, gender, or type of acne. Additionally, there were no restrictions on the study design of the included studies. The search strategy employed the keywords “topical,” “dapsone,” and “acne,” yielding 84 results. The articles were reviewed, and a second search was conducted using the keywords “topical,” “dapsone,” and “rosacea.” Extracted data included year of publication, country, study design, sample size, female to male sample size, treatment dose, course of treatment, and safety and effectiveness measures. Identified articles were screened independently by the two authors, and any discrepancies between them were resolved by consensus. Articles that met the inclusion criteria of the study were included and their findings were summarized narratively and presented in the tables highlighted below.

Discussion

Safety and adverse effects: comparing oral vs topical formulations, single vs combination therapy approaches

The most common adverse effects encountered with oral dapsone were gastrointestinal. Other less common adverse effects included: pulmonary eosinophilia, hepatitis, and muscle weakness.[21] Compared to the oral form, the topical formulation of dapsone has been implicated in a few mild side effects, affecting 2–75% of patients.[1,5] Cutaneous side effects included skin oiliness, skin dryness, erythema, localized skin pain, and a burning sensation, with these symptoms usually improving throughout the course of therapy. Combining topical dapsone with topical benzoyl peroxide resulted in a yellow discoloration in the skin and facial hair.[22] Non-cutaneous adverse effects included headaches, nasopharyngitis, and upper respiratory tract infections. The rate of occurrence of these side effects, however, was comparable to that of control groups.[4,23] In terms of serious systemic adverse effects, there have been reports of methemoglobinemia and hemolytic anemia, some even following a single application.[24]

There are two FDA-approved concentrations of topical dapsone: 5% applied twice daily and a 7.5% concentration to be applied once daily.[25] In terms of efficacy, topical dapsone is effective in reducing both inflammatory and non-inflammatory acne lesions.[26] A delay was noted in the improvement of non-inflammatory acne compared to inflammatory acne. There was also a delay in the improvement of comedonal acne with 5% topical dapsone as compared to the 7.5% concentration, when both concentrations were compared to other comedolytic agents, such as topical retinoids. Thus, it has been recommended to combine 5% topical dapsone with other comedolytic agents for the management of comedonal acne to achieve a more rapid onset of action.[23]

The location of acne lesions does not appear to affect the efficacy of topical dapsone. Truncal acne is frequently encountered in patients with facial acne. A 7.5% dapsone gel was evaluated in the management of truncal acne and determined to be effective in reducing both inflammatory and non-inflammatory lesions, with a statistically significant percentage change in lesion counts from baseline at all time points.[27]

Topical dapsone may be used as a single therapy or in combination with other therapies, such as topical retinoids or benzoyl peroxide. Combining topical dapsone with topical retinoids nearly doubled the treatment success rate compared to topical retinoids alone.[5] A 12-week randomized controlled trial evaluated three combinations of 5% dapsone gel: one with a moisturizer, one with adapalene, and one with benzoyl peroxide. No statistically significant difference was found in the reduction of inflammatory lesions among the three groups. However, there was a significantly better response in the non-inflammatory lesion count in the group that received the dapsone and adapalene combination. Furthermore, the adverse effects reported from each combination were mild.[28] Another randomized controlled trial evaluated the safety and efficacy of 5% dapsone gel in combination with 0.1% tazarotene cream. Patients were randomized to receive either a combination of the treatments or tazarotene monotherapy. Those receiving the combination therapy experienced a greater reduction in non-inflammatory (comedonal) lesions compared to those receiving tazarotene monotherapy. Both groups tolerated the treatments well.[29]

An eight-week study was conducted to evaluate the safety and effectiveness of dapsone gel 5% as a combination therapy with oral isotretinoin in the treatment of moderate-to-severe acne vulgaris. All patients in the study were taking isotretinoin, but were divided into two groups to also receive either 5% dapsone gel or a vehicle gel. Patients applying dapsone experienced a significantly higher reduction in the number of lesions, with mild and tolerable side effects.[30]

Combining topical dapsone with doxycycline hyclate also yielded favorable results. All the participants achieved treatment success after 12 weeks of this combination. Eighty-two percent of the participants maintained their results after an additional 12 weeks of topical dapsone alone.[5]

Acne with comorbidities

A study was conducted on patients with facial and truncal acne who are also G6PD deficient to evaluate whether dapsone 5% gel induces hemolytic anemia. Subjects applied dapsone gel in acne-affected areas over the face, neck, and trunk, twice daily for 12 weeks. No clinical or laboratory evidence of hemolytic anemia was observed after treatment with topical dapsone.[31]

Another study also emphasized the safety profile of dapsone, concluding that there was no risk of hemolysis in patients with G6PD deficiency. It also expanded on the safety of topical dapsone use in patients with sulfonamide allergies. Dapsone is structurally similar to sulfonamides but is not considered a sulfonamide; hence, there is no cross-reaction.[32]

Acne is also a common skin concern during pregnancy and breastfeeding. Topical dapsone is likely safe for use during pregnancy due to its limited systemic absorption; however, it is still categorized by the FDA as pregnancy category C, with animal studies showing adverse effects.[33] It has been recommended to discontinue it during the last month of pregnancy to minimize the risk of neonatal hyperbilirubinemia. Topical dapsone is transmitted in breast milk; therefore, it has an L4 rating based on the Hale lactation risk and is not recommended for acne treatment during lactation.[34]

Role of dapsone in acne rosacea

Given dapsone’s anti-inflammatory and anti-angiogenic properties, its use in rosacea is justified. The efficacy of topical dapsone has been demonstrated in erythematotelangiectatic rosacea in a study that enrolled 35 patients diagnosed with the condition. The patients applied dapsone 5% gel to their faces twice daily for 12 weeks. All participants experienced a statistically significant improvement in the Investigator’s Global Assessment (IGA) scores, with treatment success rates reaching 62.9%, at the end of the study. Only three participants experienced mild side effects, all of which were cutaneous in nature.[35] A double-blind, randomized controlled trial, enrolling 56 patients diagnosed with papulopustular rosacea, concluded that dapsone 5% gel was equally effective as metronidazole 0.75% gel.[36]

Safety and efficacy of topical dapsone in skin of color

Tables 1 and 2 summarize the characteristics of four studies that examined the efficacy of dapsone gel depending on varying patient demographics. Two of the identified studies were conducted in the United States, and the other two were conducted in both the United States and Canada. The sample size of the intervention group ranged between 781 and 2,158 patients. The number of females exceeded that of males for all included studies, ranging from 753 to 1,413 patients. The four studies were based on randomized, double-blind controlled trials.

Table 1.

Characteristics of previous studies that examined the efficacy of dapsone gel

Author(s) and year Country Sample size for intervention and control groups Number of female to male for intervention and control groups Study design
Tanghetti et al.[40] United States and Canada 1,453/1,445 patients 753 females, 700 males/767 female, 678 males Phase 3 randomized, double-blind, and vehicle-controlled trials
Draelos et al.[43] United States and Canada 2,158/2182 patients 1,413 females, 745 males/1,416 females, 766 males Randomized, double-blind, vehicle-controlled clinical trials
Taylor et al.[37] United States 2,158/2,169 patients 1,413 females, 745 males/1,408 females, 761 males Phase 3, randomized, double-blind, vehicle-controlled studies
Del Rosso et al.[41] United States 781/3,010 patients 781 females (n=347, adolescent girls 12–17 years) with no males in the study Randomized, double-blind Phase 3 clinical trials

Table 2.

Characteristics of studies interventions

Author(s) and year Intervention and control Course of treatment Used instrument for acne vulgaris evaluation
Tanghetti et al.[40] 5% dapsone gel twice daily/vehicle twice daily 12 weeks Global acne assessment score (GAAS)
Draelos et al.[43] Once-daily topical dapsone gel, 7.5%. 12 weeks Global acne assessment score (GAAS)
Taylor et al.[37] Dapsone gel, 7.5% or vehicle once daily 12 weeks Global acne assessment score (GAAS)
Del Rosso et al.[41] Dapsone 5% gel twice daily versus vehicle gel 12 weeks Global acne assessment score (GAAS)

Evaluating responses to acne medications based on skin phototype is vital, as responses may differ in different skin types, as well as the occurrence and severity of adverse effects. Studies have highlighted the safety and efficacy of both concentrations of dapsone gel in different skin phototypes. Table 3 presents the findings of previous literature on the safety and efficacy of topical dapsone gel. A 12-week study evaluated patients’ response to dapsone 7.5% gel by categorizing them into two subgroups: skin phototypes I–III and types IV–VI, and comparing dapsone to a vehicle. Dapsone significantly improved both inflammatory and non-inflammatory lesions in both subgroups, as well as total lesion count, with the incidence of adverse effects being similar between the two groups.[37] In Table 3, another study specifically evaluated the response to dapsone 5% gel in skin of color (defined as Fitzpatrick skin types IV, V, and VI). Dapsone was applied twice daily over facial acne, with significant improvements observed in both inflammatory and comedonal lesions as well as in acne severity. The medication was also well tolerated by the study subjects, with no treatment-related adverse effects reported.[38]

Table 3.

Summary of efficacy measures of dapsone gel from previous literature

Author (s) and year Intervention and control Main findings
Tanghetti et al.[40] 5% dapsone gel twice daily/vehicle twice daily for 12 weeks Reduction in acne lesion counts was greater in females in both groups.
Reduction in total lesion counts in dapsone-treated females was higher (46.6%).
Reductions in papulopustular and comedonal lesion counts were significantly higher in females.
Higher success rate among dapsone-treated females (48.6%).
Draelos et al.[43] Once-daily topical dapsone gel, 7.5% 12 weeks Greater overall and for all subgroups versus vehicle. GAAS success rates and mean decrease in all lesion counts with dapsone gel, 7.5% were greater in older (aged above 18 years) versus younger patients, and for females versus males.
Treatment response with dapsone gel, 7.5% in racial subgroups was similar.
Age group and sex were identified as predictors of GAAS success and reduction in lesion counts.
Adverse events were similar across subgroups.
Taylor et al.[37] Dapsone gel, 7.5% or vehicle once daily 12 weeks Dapsone gel, 7.5% improved acne severity versus vehicle in both skins phototype subgroups, as determined by the percentage of patients with at least a 1-grade improvement in GAAS.
Dapsone gel, 7.5% reduced inflammatory, comedonal, and total lesions in skin phototypes I–III and IV–VI versus vehicle.
Del Rosso et al.[41] Dapsone 5% gel twice daily versus vehicle gel 12 weeks Dapsone 5% gel improved acne vulgaris in both adolescents and adults.
Clinical success (GAAS score 0 or 1) was greater in adult women (53.5%) than in adolescents.
5% gel resulted in reductions in inflammatory, non-inflammatory, and total lesion counts.

GAAS=Global acne assessment score

Gender, age, and race

Women are more prone to acne vulgaris than men, driving a need for effective therapies. A post hoc analysis evaluated 2160 patients with facial acne who received either dapsone 7.5% gel or a vehicle, applied once daily for 12 weeks. Females displayed superior efficacy with dapsone gel when compared to males, with similar tolerability to the drug across both groups.[39]

The influence of gender on the efficacy of 5% topical dapsone was also evaluated, using data from two randomized, double-blind, and vehicle-controlled trials. Females experienced a significantly higher reduction in total lesion counts, comedonal and papulopustular lesions as compared to males, proving that gender is a predictor of treatment response to topical dapsone[40] [Table 3].

Age may also play a role in treatment outcomes, with an increasing rate of post-adolescent women seeking effective and safe treatments for acne vulgaris.[40] A subgroup analysis was conducted based on data from two studies that compared dapsone 5% gel to a vehicle gel, each applied twice daily, and stratified patients in each group by age: adolescent (12–17 years) or post-adolescent/adult (>17 years). Reductions in inflammatory lesions were similar between the adolescent and adult groups. However, a higher reduction in non-inflammatory and total lesion counts was observed in the adult female group, suggesting a higher overall efficacy of 5% dapsone gel in this group. The drug was tolerated well in both groups.[41] In Table 3, topical dapsone is also effective in the treatment of acne vulgaris in pre-adolescent patients, in which the 7.5% gel is indicated for the treatment of acne vulgaris in patients older than nine years.[42]

Another subgroup analysis aimed to investigate the impact of age, gender, and race (Caucasian vs. non-Caucasian) on treatment response to 7.5% dapsone gel. Older age groups (≥18 years) and female gender were predictors of a higher treatment response as compared to their counterparts, with similar treatment responses in both Caucasian and non-Caucasian patients. Side effects were similar across all groups[43] [Table 3].

Conclusion

Topical dapsone, in both the 5% and 7.5% concentrations, has proven to be effective and safe. This conclusion stands regardless of existing comorbidities, gender, race, skin phototype, and age. Acne patients suffer tremendously and require more viable long-term options for their chronic and frequently stubborn condition. We hope this review highlights the difference in safety profiles between topical dapsone and its oral counterpart, leading to less hesitancy in prescribing the topical form and encouraging physicians to add it to their armamentarium for acne management.

Conflicts of interest

There are no conflicts of interest.

Funding Statement

Nil.

References

  • 1.Pickert A, Raimer S. An evaluation of dapsone gel 5% in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10:1515–21. doi: 10.1517/14656560903002097. [DOI] [PubMed] [Google Scholar]
  • 2.Searle T, Al-Niaimi F, Ali FR. Dapsone for acne: Still in use after half a century! J Cosmet Dermatol. 2021;20:2036–9. doi: 10.1111/jocd.14011. [DOI] [PubMed] [Google Scholar]
  • 3.Kurien G. Dapsone. U. S. National Library of Medicine. 2024. [[Last accessed on 2024 Oct 28]]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470552/
  • 4.Wang X, Wang Z, Sun L, Liu H, Zhang F. Efficacy and safety of dapsone gel for acne: A systematic review and meta-analysis. Ann Palliat Med. 2022;11:611–20. doi: 10.21037/apm-21-3935. [DOI] [PubMed] [Google Scholar]
  • 5.Nickles MA, Lake E. Topical dapsone in the treatment of acne: A systematic review. Int J Dermatol. 2022;61:1412–21. doi: 10.1111/ijd.16074. [DOI] [PubMed] [Google Scholar]
  • 6.Vasam M, Korutla S, Bohara RA. Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances. Biochemistry and Biophysics Reports. 2023;36:101578. doi: 10.1016/j.bbrep.2023.101578. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Tan A, Schlosser B, Paller A. A review of diagnosis and treatment of acne in adult female patients. Int J Women's Dermatol. 2018;4:56–71. doi: 10.1016/j.ijwd.2017.10.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Kosmadaki M, Katsambas A. Topical treatments for acne. Clin Dermatol. 2017;35:173–8. doi: 10.1016/j.clindermatol.2016.10.010. [DOI] [PubMed] [Google Scholar]
  • 9.Dapsone topical: Medlineplus Drug Information. U. S. National Library of Medicine. [[Last accessed on 2024 Oct 28]]. Available from: https://medlineplus.gov/druginfo/meds/a616045.html .
  • 10.Once-daily topical dapsone gel 7.5% for acne vulgaris: Pooled efficacy and safety data from two pivotal studies. J Am Acad Dermatol. 2016;74:AB7. [Google Scholar]
  • 11.Rao MR, Deshpande S, Deshpande P. Dapsone-loaded mixed micellar gel for treatment OF acne vulgaris. AAPS PharmSciTech. 2023;24:109. doi: 10.1208/s12249-023-02564-1. [DOI] [PubMed] [Google Scholar]
  • 12.Dapsone. U. S. National Library of Medicine. 2024. [[Last accessed on 2024 Oct 28]]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501589/
  • 13.Pharmacokinetics of 5% dapsone topical gel demonstrates minimal systemic exposure. Pharmacokinetics of 5% dapsone topical gel demonstrates minimal systemic exposure. J Am Acad Dermatol. 2005;52:P20. [Google Scholar]
  • 14.Thiboutot DM, Willmer J, Sharata H, Halder R, Garrett S. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharm. 2007;46:697–712. doi: 10.2165/00003088-200746080-00006. [DOI] [PubMed] [Google Scholar]
  • 15.Jarratt MT, Jones TM, Chang-Lin JE, Tong W, Berk DR, Lin V, et al. Safety and pharmacokinetics of once-daily dapsone gel, 7.5% in patients with moderate acne vulgaris. J Drugs Dermatol. 2016;15:1250–9. [PubMed] [Google Scholar]
  • 16.Stotland M, Shalita AR, Kissling RF. Dapsone 5% Gel. Am J Clin Dermatol. 2009;10:221–7. doi: 10.2165/00128071-200910040-00002. [DOI] [PubMed] [Google Scholar]
  • 17.Yale S, Stefanko N, McCarthy P, McFadden V, McCarthy J. Severe methemoglobinemia due to topical dapsone misuse in a teenage girl. Pediatr Dermatol. 2020;37:377–8. doi: 10.1111/pde.14080. [DOI] [PubMed] [Google Scholar]
  • 18.Cantrell C, Costers V, Wilson CC, Dudek CJ, Arnold JK. Refractory methemoglobinemia secondary to topical dapsone with subsequent autoimmune hemolytic anemia. Cureus. 2022;14:e28811. doi: 10.7759/cureus.28811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Al-Salama ZT, Deeks ED. Dapsone 7.5% gel: A review in acne vulgaris. Am J Clin Dermatol. 2017;18:139–45. doi: 10.1007/s40257-016-0242-0. [DOI] [PubMed] [Google Scholar]
  • 20.Stockton TC, Tanghetti EA, Lain E, Zeichner JA, Alvandi N. Clinical experience with once-daily dapsone gel, 7.5% monotherapy in patients with acne vulgaris. J Drugs Dermatol. 2018;17:602–8. [PubMed] [Google Scholar]
  • 21.Lovell KK, Momin RI, Sangha HS, Feldman SR, Pichardo RO. Dapsone use in dermatology. Am J Clin Dermatol. 2024;25:811–22. doi: 10.1007/s40257-024-00879-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dubina MI, Fleischer AB. Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. Arch Dermatol. 2009;145:1027–9. doi: 10.1001/archdermatol.2009.186. [DOI] [PubMed] [Google Scholar]
  • 23.Draelos ZD, Carter E, Maloney JM, Elewski B, Poulin Y, Lynde C, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439.e1–439.e10. doi: 10.1016/j.jaad.2006.10.005. [DOI] [PubMed] [Google Scholar]
  • 24.Graff DM, Bosse GM, Sullivan J. Case report of methemoglobinemia in a toddler secondary to topical dapsone exposure. BMC Pediatr. 2016:138. doi: 10.1542/peds.2015-3186. [DOI] [PubMed] [Google Scholar]
  • 25.Treetanuchai J, Khuancharee K, Lertphanichkul C, Rojhirunsakool S. Efficacy and safety of topical dapsone for acne vulgaris: A systemic review with meta-analysis. Dermatol Ther 2024. 2024:3092910. [Google Scholar]
  • 26.Lucky AW, Maloney JM, Roberts J, Taylor S, Jones T, Ling M, et al. Dapsone gel long-term safety study group dapsone gel 5% for the treatment of acne vulgaris: Safety and efficacy of long-term (1 year) treatment. J Drugs Dermatol. 2007;6:981–7. [PubMed] [Google Scholar]
  • 27.Del Rosso JQ, Kircik L, Tanghetti E. Management of truncal acne vulgaris with topical dapsone 7.5% gel. J Clin Aesthet Dermatol. 2018;11:45–50. [PMC free article] [PubMed] [Google Scholar]
  • 28.Fleischer AB, Jr, Fleischer AB, Jr, Shalita A, Eichenfield LF, Abramovits W, Lucky A, et al. Dapsone gel in combination treatment study group dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: A 12-week, randomized, double-blind study. J Drugs Dermatol. 2010;9:33–40. [PubMed] [Google Scholar]
  • 29.Tanghetti E, Dhawan S, Green L, Ling M, Downie J, Germain MA, et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: Findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J Drugs Dermatol. 2011;10:783–92. [PubMed] [Google Scholar]
  • 30.Faghihi G, Rakhshanpour M, Abtahi-Naeini B, Nilforoushzadeh MA. The efficacy of 5% dapsone gel plus oral isotretinoin versus oral isotretinoin alone in acne vulgaris: A randomized double-blind study. Adv Biomed Res. 2014;3:177. doi: 10.4103/2277-9175.139413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Piette WW, Taylor S, Pariser D, Jarratt M, Sheth P, Wilson D. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol. 2008;144:1564–70. doi: 10.1001/archdermatol.2008.518. [DOI] [PubMed] [Google Scholar]
  • 32.Webster GF. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol. 2010;9:532–6. [PubMed] [Google Scholar]
  • 33.Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. Nordisk Alkohol Nark. 2013;73:779–87. doi: 10.1007/s40265-013-0060-0. [DOI] [PubMed] [Google Scholar]
  • 34.Ly S, Kamal K, Manjaly P, Barbieri JS, Mostaghimi A. Treatment of acne vulgaris during pregnancy and lactation: A narrative review. Dermatol Ther. 2023;13:115–30. doi: 10.1007/s13555-022-00854-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gökşin Ş, Göğem İmren I, Kaçar N. Efficacy of topical dapsone 5% gel for the treatment of erythematotelangiectatic rosacea: New treatment option with old drug. Dermatol Pract Concept. 2024;14:e2024034. doi: 10.5826/dpc.1401a34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Faghihi G, Khosravani P, Nilforoushzadeh MA, Hosseini SM, Assaf F, Zeinali N, et al. Dapsone gel in the treatment of papulopustular rosacea: A double-blind randomized clinical trial. J Drugs Dermatol. 2015;14:602–6. [PubMed] [Google Scholar]
  • 37.Taylor SC, Cook-Bolden FE, McMichael A, Downie JB, Rodriguez DA, Alexis AF, et al. Efficacy, safety, and tolerability of topical dapsone gel, 7.5% for treatment of acne vulgaris by fitzpatrick skin phototype. J Drugs Dermatol. 2018;17:160–7. [PubMed] [Google Scholar]
  • 38.Alexis AF, Burgess C, Callender VD, Herzog JL, Roberts WE, Schweiger ES, et al. The efficacy and safety of topical dapsone gel, 5% for the treatment of acne vulgaris in adult females with skin of color. J Drugs Dermatol. 2016;15:197–204. [PubMed] [Google Scholar]
  • 39.Tanghetti E, Harper J, Baldwin H, Kircik L, Bai Z, Alvandi N. Once-daily topical dapsone gel, 7.5%: Effective for acne vulgaris regardless of baseline lesion count, with superior efficacy in females. J Drugs Dermatol. 2018;17:1192–8. [PubMed] [Google Scholar]
  • 40.Tanghetti E, Harper JC, Oefelein MG. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: Gender as a clinically relevant outcome variable. J Drugs Dermatol. 2012;11:1417–21. [PubMed] [Google Scholar]
  • 41.Del Rosso JQ, Kircik L, Gallagher CJ. Comparative efficacy and tolerability of dapsone 5% gel in adult versus adolescent females with acne vulgaris. J Clin Aesth Dermatol. 2015;8:31–7. [PMC free article] [PubMed] [Google Scholar]
  • 42.Moore AY, Lain EL, McMichael A, Kircik L, Zaenglein AL, Hebert AA, et al. Once-daily Dapsone 7.5% gel for the treatment of acne vulgaris in preadolescent patients: A phase IV, open-label, 12-week study. J Clin Aesthet Dermatol. 2021;14:43–8. [PMC free article] [PubMed] [Google Scholar]
  • 43.Draelos ZD, Rodriguez DA, Kempers SE, Bruce S, Peredo MI, Downie J, et al. Treatment response with once-daily topical dapsone gel, 7.5% for acne vulgaris: Subgroup analysis of pooled data from two randomized, double-blind stu. J Drugs Dermatol. 2017;16:591–8. [PubMed] [Google Scholar]

Articles from Journal of Family Medicine and Primary Care are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES